123 related articles for article (PubMed ID: 32873918)
1. External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study.
Stolzenbach LF; Deuker M; Collà-Ruvolo C; Nocera L; Mansour M; Tian Z; Tilki D; Steuber T; Briganti A; Saad F; Chun FKH; Graefen M; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):253-260. PubMed ID: 32873918
[TBL] [Abstract][Full Text] [Related]
2. Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients.
Wenzel M; Collà Ruvolo C; Würnschimmel C; Nocera L; Tian Z; Saad F; Briganti A; Tilki D; Graefen M; Becker A; Roos F; Mandel P; Chun FKH; Karakiewicz PI
Prostate; 2022 Jan; 82(1):78-85. PubMed ID: 34633102
[TBL] [Abstract][Full Text] [Related]
3. External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA.
Stolzenbach LF; Rosiello G; Deuker M; Martin T; Knipper S; Tian Z; Briganti A; Zorn KC; Saad F; Chun FKH; Graefen M; Karakiewicz PI
Urol Oncol; 2021 Feb; 39(2):131.e1-131.e7. PubMed ID: 33189532
[TBL] [Abstract][Full Text] [Related]
4. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
Pompe RS; Tilki D; Preisser F; Leyh-Bannurah SR; Bandini M; Marchioni M; Gild P; Tian Z; Fossati N; Cindolo L; Shariat SF; Huland H; Graefen M; Briganti A; Karakiewicz PI
Prostate; 2018 Jul; 78(10):753-757. PubMed ID: 29663462
[TBL] [Abstract][Full Text] [Related]
6. Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study.
Stolzenbach LF; Deuker M; Collà-Ruvolo C; Nocera L; Tian Z; Maurer T; Steuber T; Tilki D; Briganti A; Saad F; Chun FK; Graefen M; Karakiewicz PI
Int J Urol; 2021 Aug; 28(8):834-839. PubMed ID: 34047401
[TBL] [Abstract][Full Text] [Related]
7. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
[TBL] [Abstract][Full Text] [Related]
8. Surgery associated with increased survival compared to radiation in clinically localized Gleason 9-10 prostate cancer: a SEER analysis.
Nemirovsky A; Huang H; Al Kibria GM; Naslund M; Siddiqui MM
World J Urol; 2021 Feb; 39(2):415-423. PubMed ID: 32350585
[TBL] [Abstract][Full Text] [Related]
9. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
10. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients.
Knipper S; Dzyuba-Negrean C; Palumbo C; Pecoraro A; Rosiello G; Tian Z; Briganti A; Saad F; Tilki D; Graefen M; Karakiewicz PI
Int Urol Nephrol; 2020 Jan; 52(1):59-66. PubMed ID: 31542882
[TBL] [Abstract][Full Text] [Related]
11. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
12. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
[TBL] [Abstract][Full Text] [Related]
13. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.
Fossati N; Trinh QD; Sammon J; Sood A; Larcher A; Sun M; Karakiewicz P; Guazzoni G; Montorsi F; Briganti A; Menon M; Abdollah F
Eur Urol; 2015 Jan; 67(1):3-6. PubMed ID: 25217422
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.
Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Montorsi F; Graefen M; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2019 Sep; 2(5):541-548. PubMed ID: 31411992
[TBL] [Abstract][Full Text] [Related]
15. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.
Brachman DG; Thomas T; Hilbe J; Beyer DC
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):111-7. PubMed ID: 10924979
[TBL] [Abstract][Full Text] [Related]
16. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis.
Knipper S; Palumbo C; Pecoraro A; Rosiello G; Tian Z; Briganti A; Zorn KC; Saad F; Tilki D; Graefen M; Karakiewicz PI
Urol Oncol; 2020 Mar; 38(3):79.e9-79.e14. PubMed ID: 31653563
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.
Preisser F; Bandini M; Nazzani S; Mazzone E; Marchioni M; Tian Z; Chun FKH; Saad F; Briganti A; Haese A; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Oncol; 2020 Oct; 3(5):631-639. PubMed ID: 31411975
[TBL] [Abstract][Full Text] [Related]
19. Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer.
Miao Q; Wei Z; Liu C; Ye Y; Cheng G; Song Z; Chen K; Zhang Y; Chen J; Yue C; Ruan H; Zhang X
Front Oncol; 2023; 13():1130680. PubMed ID: 37207146
[TBL] [Abstract][Full Text] [Related]
20. Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis.
Moschini M; Morlacco A; Kwon E; Rangel LJ; Karnes RJ
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):117-121. PubMed ID: 28045114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
